Janssen Korea on Monday launched Sirturo, a treatment for multi-drug-resistant tuberculosis.
Sirturo has been shown to reduce the treatment period by 42 days compared to conventional treatment using drugs normally prescribed in Korea. In a clinical test, it cured 57.9 percent of tested people within 120 weeks.
The drug was approved by the Korea Food and Drug Administration on March 21.
In Korea, 1,212 people reportedly contract MDR-TB every year. Korea’s MDR-TB prevalence and death rate from the disease is the highest among OCED states.
